Market research
OTLK OUTLOOK THERAPEUTICS INC
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 4.9
- Dividend yield
- Not available
- Beta
- 0.8
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US69012T3059
- Market cap
- 148M
- P/E ratio
- Not available
- Analyst target
- 4.9
- Dividend yield
- Not available
- Beta
- 0.8
About
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OTLK discussion.
5 years, 4 months ago
Outlook Therapeutics, Inc is currently in a long term uptrend where the price is trading 40.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.3.
Outlook Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 12.9% to $-14M since the same quarter in the previous year.
Finally, its free cash flow fell by 99.7% to $-13M since the same quarter in the previous year.
Based on the above factors, Outlook Therapeutics, Inc gets an overall score of 3/5.